Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDP-003 in Healthy Participants and Patients with Acute Coronary Syndrome
NCT06813339Phase 1Recruiting
- Sponsor
- Cyclarity Therapeutics
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute coronary syndrome (ACS) comparing UDP-003 with Placebo (2 arms). Primary endpoints: Adverse Events at 28 weeks, Systolic Blood Pressure at 28 weeks and 11 more. Started Feb 2025; status: recruiting.
02
Drugs
UDP-003
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06813339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813339.